Early Trials

In 2017 the company presented pre-clinical data demonstrating tumor response in its lead CAR-T product candidate, P-BCMA-101 in multiple myeloma, followed soon after by pre-clinical data for P-PSMA-101 in prostate cancer showing potent anti-tumor activity and persistent, durable responses. In December 2017, Poseida received a grant from The California Institute for Regenerative Medicine (CIRM) to support the Phase 1 clinical trial for P-BCMA-101. The first BCMA patient in the trial was dosed later that year.